Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neo-adjuvant FOLFOXIRI and chemoradiotherapy for high-risk locally advanced rectal cancer
2023-509758-74-00Phase 2Authorised
- Sponsor
- Catharina Ziekenhuis
- Start
- Mar 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irinotecan, oxaliplatin, fluorouracil and folinic acid in rectal cancer and locally advanced rectal cancer (LARC), sponsored by Catharina Ziekenhuis. Primary endpoint: Pathological and clinical complete response at 1 year. Planned start Mar 2024; status: authorised.
02
Drugs
irinotecanoxaliplatinfluorouracilfolinic acid
03
Conditions
rectal cancerlocally advanced rectal cancer (LARC)
Beyond the preview
Go deeper on 2023-509758-74-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509758-74-00.